/
DCF Valuation
Base-case fair value
$21.88
Intrinsic $29.17 · 25% MOS
Current price: $55.00
Base-case summary
Our base-case DCF for BIO-TECHNE Corp (TECH) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $270M in trailing free cash flow, this produces an intrinsic value of $29.17 per share. A 25% safety margin gives a fair value of $21.88, suggesting the stock is currently 60% overvalued against the $55.00 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$270M
Cash & equivalents
$210M
Total debt
$290M
Shares outstanding
157M